{"id":"livalov","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia (muscle pain)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LivaloV (pitavastatin) is a selective and potent inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By blocking this enzyme, it reduces hepatic cholesterol production, leading to decreased serum LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. This mechanism helps reduce cardiovascular risk in patients with dyslipidemia.","oneSentence":"LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:06.705Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"}]},"trialDetails":[{"nctId":"NCT05331014","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-11-15","conditions":"Dyslipidemia, Hypertension","enrollment":155},{"nctId":"NCT05351840","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2020-11-02","conditions":"Healthy","enrollment":31},{"nctId":"NCT04270344","phase":"","title":"The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment","status":"UNKNOWN","sponsor":"JW Pharmaceutical","startDate":"2018-07-01","conditions":"Hypercholesterolemia","enrollment":905}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JW0101+C2102","Period I"],"phase":"phase_3","status":"active","brandName":"LivaloV","genericName":"LivaloV","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}